{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:09:14Z","timestamp":1776805754108,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.mehy.2020.109740","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T01:53:05Z","timestamp":1586742785000},"page":"109740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Rapid reduction in uric acid by a urate-lowering agent is associated with recurrent cardiovascular events"],"prefix":"10.1016","volume":"141","author":[{"given":"Jung Sun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Keun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mehy.2020.109740_b0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/art.23121","article-title":"Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study","volume":"58","author":"Ioachimescu","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mehy.2020.109740_b0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-011-0234-2","article-title":"Association between gout and all-cause as well as cardiovascular mortality: a systematic review","volume":"14","author":"Lottmann","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.mehy.2020.109740_b0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12872-017-0513-6","article-title":"Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes","volume":"17","author":"Singh","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"10.1016\/j.mehy.2020.109740_b0020","first-page":"393","article-title":"Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor","volume":"10","author":"Foody","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"13","key":"10.1016\/j.mehy.2020.109740_b0025","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mehy.2020.109740_b0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout Initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.mehy.2020.109740_b0035","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kex065","article-title":"Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis","volume":"56","author":"Zhang","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mehy.2020.109740_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"issue":"Suppl 1","key":"10.1016\/j.mehy.2020.109740_b0045","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1908","article-title":"The inflammatory process of gout and its treatment","volume":"8","author":"Cronstein","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"16","key":"10.1016\/j.mehy.2020.109740_b0050","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mehy.2020.109740_b0055","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mehy.2020.109740_b0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2011.04.035","article-title":"The chronic kidney disease epidemiology collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the modification of diet in renal disease (MDRD) study formula in subjects with type 2 diabetes","volume":"218","author":"Pugliese","year":"2011","journal-title":"Atherosclerosis"},{"issue":"16","key":"10.1016\/j.mehy.2020.109740_b0065","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation\/American heart association task force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mehy.2020.109740_b0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1590\/S1679-45082013000300022","article-title":"Decompensated heart failure","volume":"11","author":"Mangini","year":"2013","journal-title":"Einstein (Sao Paulo)"},{"issue":"3","key":"10.1016\/j.mehy.2020.109740_b0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.40744","article-title":"Febuxostat does not increase all-cause mortality and cardiovascular mortality compared with placebo: comment on the article by Choi et al.","volume":"71","author":"Kuwabara","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.mehy.2020.109740_b0080","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15257770802138558","article-title":"Uric acid: the oxidant-antioxidant paradox","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotides Nucl Acids"},{"issue":"11","key":"10.1016\/j.mehy.2020.109740_b0085","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis","volume":"78","author":"Ames","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.mehy.2020.109740_b0090","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2337\/db13-1396","article-title":"Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects","volume":"63","author":"Fabbrini","year":"2014","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.mehy.2020.109740_b0095","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American college of rheumatology guidelines for management of gout: Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.mehy.2020.109740_b0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mehy.2020.109740_b0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","article-title":"Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study","volume":"20","author":"Gunawardhana","year":"2018","journal-title":"Arthritis Res Ther"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720301766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720301766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:22:33Z","timestamp":1759692153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720301766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":21,"alternative-id":["S0306987720301766"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109740","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid reduction in uric acid by a urate-lowering agent is associated with recurrent cardiovascular events","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109740"}}